- The V-Go (Valeritas, Inc.) may improve glycemic control and reduce costs in patients who require basal-bolus insulin delivery.
Why this matters
- Frequency and timing of insulin injections are often barriers to achieving glycemic control.
- Retrospective record review, 103 adults with diabetes (96% type 2) and baseline HbA1c >7% who initiated V-Go, including 22% insulin-naive, 56% previously receiving basal-bolus injection regimens, followed 14 months.
- Funding: Valeritas, Inc.
- Significant mean reductions from baseline were seen in HbA1c at all points, with 82% below baseline at 14 months.
- The percentage of patients with HbA1c >9.0% dropped from 59% to 26%, whereas 50% vs 17%, respectively, achieved HbA1c
- Among 80 using insulin at baseline, mean total daily dose dropped by 17 units/day (P<.0001>
- Cost savings from decreased total daily insulin dose exceeded V-Go cost, with $25 overall decrease per patient per month after switching from injection basal-bolus regimen.
- Patients gained a mean 3.18 kg (P=.029) body weight, but those already receiving basal-bolus insulin gained just 0.26 kg (P=.897).
- There was no increase in patient-reported hypoglycemia or device malfunctions.
- Retrospective observational study.
- Cost calculated from prescriptions, not actual use.
- Nonreturning patients excluded.
- Hypoglycemia was self-reported.